Intraperitoneal (IP) chemotherapy has shown promising efficacy in ovarian cancer with
peritoneal carcinomatosis (PC), but in vivo rapid clearance and severe toxicity of free …

Advanced staged high‐grade serous ovarian cancer (HGSOC) is the leading cause of
gynecological cancer death in the developed world, with 5‐year survival rates of only 25 …

The ip administration of chemotherapy in ovarian and uterine serous carcinoma patients by
biodegradable nanoparticles may represent a highly effective way to suppress peritoneal …

Multiple combination therapies with chemotherapeutic drugs and inhibitors of drug
resistance have been effective in the clinical cases, but concerns have been raised about …

Patients with advanced ovarian cancer develop recurrence despite initial treatment
response to standard treatment of surgery and intravenous/intraperitoneal (IP) …

Intra-abdominal dissemination of peritoneal nodules, a condition known as peritoneal
carcinomatosis (PC), is typically diagnosed in ovarian cancer patients at the advanced …

Intraperitoneal (IP) chemotherapy is a promising post-surgical therapy of ovarian cancer, but
the full potential is yet to be realized. To facilitate IP chemotherapy of ovarian cancer, we …

Carcinomatosis from peritoneal surface malignancies, such as mesothelioma, appendiceal
carcinoma or ovarian metastases, significantly decreases survival and quality of life. Given a …

Background Platinum resistance is a major challenge in the management of ovarian cancer.
Even low levels of acquired resistance at the cellular level lead to impaired response to …

Nanoparticle drug delivery system (NDDS) is quite different from the widely studied
traditional chemotherapy which suffers from drug resistance and side effect. NDDS offers the …